Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,691.00GBp
11:35am EDT
Change (% chg)

-16.00 (-0.94%)
Prev Close
1,707.00
Open
1,712.50
Day's High
1,712.50
Day's Low
1,652.00
Volume
768,652
Avg. Vol
470,470
52-wk High
2,089.00
52-wk Low
1,290.00

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Overall

Beta: 0.79
Market Cap(Mil.): £4,128.55
Shares Outstanding(Mil.): 242.01
Dividend: 20.11
Yield (%): --

Financials

  HIK.L Industry Sector
P/E (TTM): 18.63 52.11 53.45
EPS (TTM): 0.92 -- --
ROI: 11.03 12.01 11.71
ROE: 17.63 13.29 16.35

UPDATE 1-Hikma backs annual outlook on demand for its new drugs

May 17 Hikma Pharmaceuticals Plc on Friday backed its forecast for the full year, boosted by higher demand for its new drugs and generic medicines.

May 17 2019

Hikma backs annual outlook boosted by medicine demand

May 17 Hikma Pharmaceuticals Plc on Friday backed its forecast for the full-year, boosted by higher demand for its injectable drugs and a rebound in its generics business.

May 17 2019

Hikma guides for injectables growth after profit surge

Hikma Pharmaceuticals Plc on Wednesday forecast growth in 2019 for its injectable drugs division, as strong demand along with a rebound in its generics business helped it post a 19 percent jump in full-year core operating profit.

Mar 13 2019

UPDATE 1-Hikma guides for injectables growth after profit surge

March 13 Hikma Pharmaceuticals Plc on Wednesday forecast growth in 2019 for its injectable drugs division, as strong demand along with a rebound in its generics business helped it post a 19 percent jump in full-year core operating profit.

Mar 13 2019

Hikma core operating profit jumps on higher sales of injectable drugs

March 13 Hikma Pharmaceuticals Plc on Wednesday reported a 19 percent rise in full-year core operating profit, helped by strong demand for its injectable drugs and a rebound in its generics business.

Mar 13 2019

Judge finds Hikma entitled to $31 mln in gout drug dispute

Hikma Pharmaceuticals PLC did not infringe rival Takeda Pharmaceutical Co's patents by selling a gout drug with the same active ingredient as Takeda's Colcrys and is entitled to $31 million in lost profits it suffered due to a prior restraining order, a Delaware federal judge has ruled.

Dec 13 2018

Earnings vs. Estimates